Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

September 01, 1994; Volume 46,Issue 3
  • You have access
    Multiple cyclic nucleotide phosphodiesterases.
    J A Beavo, M Conti and R J Heaslip
    Molecular Pharmacology September 1994, 46 (3) 399-405;
  • You have access
    Rapid heterologous desensitization of muscarinic and thrombin receptor-mediated phospholipase D activation.
    M Nieto, E Kennedy, D Goldstein and J H Brown
    Molecular Pharmacology September 1994, 46 (3) 406-413;
  • You have access
    The rat homologue of the bovine alpha 1c-adrenergic receptor shows the pharmacological properties of the classical alpha 1A subtype.
    T M Laz, C Forray, K E Smith, J A Bard, P J Vaysse, T A Branchek and R L Weinshank
    Molecular Pharmacology September 1994, 46 (3) 414-422;
  • You have access
    Occurrence and activation of Ca2+/calmodulin-dependent protein kinase II and its endogenous substrates in bovine adrenal medullary cells.
    N Yanagihara, Y Toyohira, H Yamamoto, Y Ohta, M Tsutsui, E Miyamoto and F Izumi
    Molecular Pharmacology September 1994, 46 (3) 423-430;
  • You have access
    A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
    J M Barret, P Calsou, A K Larsen and B Salles
    Molecular Pharmacology September 1994, 46 (3) 431-436;
  • You have access
    Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme.
    T Dorai, H Kobayashi, J F Holland and T Ohnuma
    Molecular Pharmacology September 1994, 46 (3) 437-444;
  • You have access
    Differential modulation of human fibroblast and keratinocyte growth by the protein kinase C inhibitor GF 109203X.
    R Le Panse, B Coulomb, V Mitev, B Bouchard, C Lebreton and L Dubertret
    Molecular Pharmacology September 1994, 46 (3) 445-451;
  • You have access
    Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
    I Johansson, M Oscarson, Q Y Yue, L Bertilsson, F Sjöqvist and M Ingelman-Sundberg
    Molecular Pharmacology September 1994, 46 (3) 452-459;
  • You have access
    Dual signaling potential is common among Gs-coupled receptors and dependent on receptor density.
    X Zhu, S Gilbert, M Birnbaumer and L Birnbaumer
    Molecular Pharmacology September 1994, 46 (3) 460-469;
  • You have access
    Deletion mutation in the putative third intracellular loop of the rat neurotensin receptor abolishes polyphosphoinositide hydrolysis but not cyclic AMP formation in CHO-K1 cells.
    M Yamada, M Yamada, M A Watson and E Richelson
    Molecular Pharmacology September 1994, 46 (3) 470-476;
  • You have access
    Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems.
    K A Berg, W P Clarke, C Sailstad, A Saltzman and S Maayani
    Molecular Pharmacology September 1994, 46 (3) 477-484;
  • You have access
    Endothelin receptor type A signals both the accumulation of inositol phosphates and the inhibition of cyclic AMP generation in rat myometrium: stimulation and desensitization.
    L D Khac, S Naze and S Harbon
    Molecular Pharmacology September 1994, 46 (3) 485-494;
  • You have access
    Internalization of the gastrin-releasing peptide receptor is mediated by both phospholipase C-dependent and -independent processes.
    R V Benya, M Akeson, J Mrozinski, R T Jensen and J F Battey
    Molecular Pharmacology September 1994, 46 (3) 495-501;
  • You have access
    Many agonists induce "quantal" Ca2+ release or adaptive behavior in muscle ryanodine receptors.
    C Dettbarn, S Györke and P Palade
    Molecular Pharmacology September 1994, 46 (3) 502-507;
  • You have access
    Does general anesthetic-induced desensitization of the Torpedo acetylcholine receptor correlate with lipid disordering?
    L L Firestone, J K Alifimoff and K W Miller
    Molecular Pharmacology September 1994, 46 (3) 508-515;
  • You have access
    Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid.
    J C Pinto, F Potié, K C Rice, D Boring, M R Johnson, D M Evans, G H Wilken, C H Cantrell and A C Howlett
    Molecular Pharmacology September 1994, 46 (3) 516-522;
  • You have access
    Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover.
    X Peng, V Gerzanich, R Anand, P J Whiting and J Lindstrom
    Molecular Pharmacology September 1994, 46 (3) 523-530;
  • You have access
    Subunit-specific potentiation of recombinant N-methyl-D-aspartate receptors by histamine.
    K Williams
    Molecular Pharmacology September 1994, 46 (3) 531-541;
  • You have access
    Phosphorylation factors control neurotransmitter and neuromodulator actions at the gamma-aminobutyric acid type A receptor.
    M Gyenes, Q Wang, T T Gibbs and D H Farb
    Molecular Pharmacology September 1994, 46 (3) 542-549;
  • You have access
    Stable expression of a neuronal gamma-aminobutyric acid transporter, GAT-3, in mammalian cells demonstrates unique pharmacological properties and ion dependence.
    J A Clark and S G Amara
    Molecular Pharmacology September 1994, 46 (3) 550-557;
  • You have access
    Pharmacological discrimination between gamma-aminobutyric acid type B receptors regulating cholecystokinin and somatostatin release from rat neocortex synaptosomes.
    A Gemignani, P Paudice, G Bonanno and M Raiteri
    Molecular Pharmacology September 1994, 46 (3) 558-562;
  • You have access
    Epoxide metabolite of quinine and inhibition of the multidrug resistance pump in human leukemic lymphoblasts.
    P W Wigler, K L Lyon, F K Patterson, A J La Loggia, H Diaz-Araúzo, M S Reddy and J M Cook
    Molecular Pharmacology September 1994, 46 (3) 562-567;
  • You have access
    Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    H Yamazaki, Z Guo, M Persmark, M Mimura, K Inoue, F P Guengerich and T Shimada
    Molecular Pharmacology September 1994, 46 (3) 568-577;
  • You have access
    Specificity and directionality of thiol effects on sinusoidal glutathione transport in rat liver.
    S C Lu, J Kuhlenkamp, J L Ge, W M Sun and N Kaplowitz
    Molecular Pharmacology September 1994, 46 (3) 578-585;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 46, Issue 3
1 Sep 1994
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics